RHYTHM PHARMACEUTICALS, INC. Contracts & Agreements
81 Contracts & Agreements
- Business Finance (15 contracts)
- Business Operations (8)
- Human Resources (21)
- Intellectual Property (6)
- Real Estate (4)
- Uncategorized (27)
- Non-Employee Director Compensation Program (Filed With SEC on August 6, 2024)
- Summary of Non-Employee Director Compensation Policy (Filed With SEC on May 7, 2024)
- Rhythm Pharmaceuticals, Inc. 2017 Equity Incentive Plan Performance Unit Agreement (Filed With SEC on May 7, 2024)
- Third Amendment to Lease, dated May 2, 2024, by and between the Registrant and 500 Boylston & 222 Berkeley Owner (DE) LLC (Filed With SEC on May 7, 2024)
- Investment Agreement, dated as of April 1, 2024, by and among Rhythm Pharmaceuticals, Inc., and the investors named therein (Filed With SEC on April 1, 2024)
- Summary of Non-Employee Director Compensation Policy (Filed With SEC on February 29, 2024)
- Exclusive License Agreement, dated January 4, 2024, by and between Rhythm Pharmaceuticals, Inc. and LG Chem, Ltd (Filed With SEC on February 29, 2024)
- Amendment No. 1 to Sales Agreement, dated as of February 29, 2024, between Rhythm Pharmaceuticals, Inc. and Cowen and Company, LLC (Filed With SEC on February 29, 2024)
- Amended & Restated Offer Letter, dated July 28, 2023, by and between the Registrant and Daivd P. Meeker (Filed With SEC on August 3, 2023)
- Amended & Restated Offer Letter, dated July 28, 2023, by and between the Registrant and Joseph Shulman (Filed With SEC on August 3, 2023)
- Amended & Restated Offer Letter, dated August 3, 2023, by and between the Registrant and Jennifer Chien (Filed With SEC on August 3, 2023)
- Amended & Restated Offer Letter, dated August 3, 2023, by and between the Registrant and Hunter Smith (Filed With SEC on August 3, 2023)
- Offer Letter, dated June 23, 2020, by and between the Registrant and Joseph Shulman (Filed With SEC on March 1, 2023)
- Description of the Registrants Securities registered pursuant to Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on March 1, 2023)
- Share Purchase Agreement, by and between Rhythm Pharmaceuticals Netherlands B.V. and Xinvento B.V., dated February 27, 2023 (Filed With SEC on March 1, 2023)
- Summary of Non-Employee Director Compensation Policy (Filed With SEC on March 1, 2023)
- Underwriting Agreement, dated as of September 14, 2022, between Rhythm Pharmaceuticals, Inc. and Cowen and Company, LLC, Stifel, Nicolaus & Company, Incorporated and Wells Fargo... (Filed With SEC on September 15, 2022)
- Revenue Interest Financing Agreement, dated June 16, 2022, by and between the Company and entities managed by HealthCare Royalty Management, LLC (Filed With SEC on August 3, 2022)
- 2022 Employment Inducement Plan and Form of Option Agreement (Filed With SEC on March 1, 2022)
- 2022 Employment Inducement Plan Form of Restricted Stock Unit Agreement (Filed With SEC on March 1, 2022)
- Summary of Non-Employee Director Compensation Policy (Filed With SEC on March 1, 2022)
- License Agreement, dated December 3, 2021, by and between the Registrant and RareStone Group Ltd (Filed With SEC on March 1, 2022)
- Consulting Agreement, dated September 11, 2021, by and between the Registrant and Murray Stewart, D.M., F.R.C.P (Filed With SEC on March 1, 2022)
- Amendment No. 1 to Amended and Restated Investors Rights Agreement, dated January 25, 2021 (Filed With SEC on November 2, 2021)
- Offer Letter, dated September 1, 2021, by and between the Registrant and Linda Shapiro Manning, M.D (Filed With SEC on November 2, 2021)
- Offer Letter, dated July 9, 2021, by and between the Registrant and Pamela Cramer (Filed With SEC on August 3, 2021)
- Summary of Non-Employee Director Compensation Policy (Filed With SEC on March 1, 2021)
- Offer Letter, dated May 10, 2018, by and between the Registrant and Simon D. Kelner (Filed With SEC on March 1, 2021)
- Offer Letter, dated September 14, 2018, by and between the Registrant and Murray Stewart M.D (Filed With SEC on March 1, 2021)
- Offer Letter, dated September 25, 2020, by and between the Registrant and Jennifer Chien (Filed With SEC on March 1, 2021)
- Underwriting Agreement, dated as of February 4, 2021, between Rhythm Pharmaceuticals, Inc. and Morgan Stanley & Co. LLC, BofA Securities, Inc., Cowen and Company, LLC and Stifel,... (Filed With SEC on February 5, 2021)
- Asset Purchase Agreement, dated as of January 5, 2021, by and between Rhythm Pharmaceuticals, Inc. and Alexion Pharmaceuticals, Inc (Filed With SEC on January 5, 2021)
- Offer Letter, dated September 4, 2020, and Indefinite Term Employment Contract, dated October 5, 2020, between Rhythm Pharmaceuticals, Inc. and Yann Mazabraud (Filed With SEC on November 2, 2020)
- Separation Agreement, dated September 30, 2020, between Rhythm Pharmaceuticals, Inc. and Nithya Desikan (Filed With SEC on November 2, 2020)
- Amendment No. 2 to Development and Manufacturing and Services Agreement, dated as of July 15, 2020, by and between the Company and Corden Pharma Brussels S.A (Filed With SEC on August 3, 2020)
- Offer Letter, dated July 16, 2020, between Rhythm Pharmaceuticals, Inc. and David P. Meeker, M.D (Filed With SEC on July 21, 2020)
- Amendment No. 1 to Development and Manufacturing and Services Agreement, dated as of February 20, 2020, by and between the Company and Corden Pharma Brussels S.A (Filed With SEC on May 4, 2020)
- Offer Letter, dated December 21, 2017, by and between the Company and Hunter C. Smith (Filed With SEC on May 4, 2020)
- Summary of Non-Employee Director Compensation Policy (Filed With SEC on May 4, 2020)
- Form of Restricted Stock Unit Award Agreement (Filed With SEC on March 2, 2020)
- Description of the Registrants Securities registered pursuant to Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on March 2, 2020)
- Consulting Agreement dated January 6, 2020 (Filed With SEC on January 8, 2020)
- Separation Agreement and General Release dated January 6, 2020 (Filed With SEC on January 8, 2020)
- Underwriting Agreement dated October 15, 2019 (Filed With SEC on October 16, 2019)
- Summary of Non-Employee Director Compensation Policy (Filed With SEC on July 25, 2019)
- First Amendment to Lease, dated April 15, 2016 (Filed With SEC on March 8, 2019)
- Offer Letter, dated September 13, 2017, by and between the Registrant and Lex H.T. Van der Ploeg (Filed With SEC on March 8, 2019)
- Second Amendment to Lease, dated August 6, 2018 (Filed With SEC on August 9, 2018)
- Offer Letter, dated September 13, 2017, by and between the Company and Keith M. Gottesdiener (Filed With SEC on August 8, 2018)
- Offer Letter, dated September 13, 2017, by and between the Company and Hunter Smith (Filed With SEC on August 8, 2018)
- Offer Letter, dated September 13, 2017, by and between the Company and Nithya Desikan (Filed With SEC on August 8, 2018)
- Form of Underwriting Agreement (Filed With SEC on June 18, 2018)
- First Amendment to the 2017 Employee Stock Purchase Plan (Filed With SEC on June 18, 2018)
- License Agreement dated March 30, 2018, by and between the Company and Takeda Pharmaceutical Company Limited (Filed With SEC on May 14, 2018)
- Summary of Non-Employee Director Compensation Policy (Filed With SEC on May 14, 2018)
- Rhythm Pharmaceuticals, Inc. 2017 Employee Stock Purchase Plan (Filed With SEC on November 14, 2017)
- 2017 Equity Incentive Plan and Form of Option Agreement and Notice of Exercise (Filed With SEC on November 14, 2017)
- 2017 Equity Incentive Plan and Form of Option Agreement and Notice of Exercise (Filed With SEC on September 25, 2017)
- Form of Underwriting Agreement (Filed With SEC on September 25, 2017)
- Form of Indemnification Agreement by and between the Registrant and its directors and officers (Filed With SEC on September 25, 2017)
- License Agreement dated January 4, 2016, by and between the Registrant and Camurus AB (Filed With SEC on September 25, 2017)
- Rhythm Pharmaceuticals, Inc. 2017 Employee Stock Purchase Plan (Filed With SEC on September 25, 2017)
- Offer Letter, dated September 13, 2017, by and between the Registrant and Keith M. Gottesdiener (Filed With SEC on September 25, 2017)
- Offer Letter, dated September 13, 2017, by and between the Registrant and Fred T. Fiedorek (Filed With SEC on September 25, 2017)
- Offer Letter, dated September 13, 2017, by and between the Registrant and Hunter Smith (Filed With SEC on September 25, 2017)
- Offer Letter, dated September 13, 2017, by and between the Registrant and Nithya Desikan (Filed With SEC on September 25, 2017)
- 2015 Equity Incentive Plan and Form of Option Agreement and Notice of Exercise (Filed With SEC on September 25, 2017)
- Offer Letter, dated November 16, 2016, by and between the Registrant and Keith M. Gottesdiener (Filed With SEC on September 5, 2017)
- Amended and Restated Investors' Rights Agreement, dated August 21, 2017, by and among the Registrant and the investors set forth therein (Filed With SEC on September 5, 2017)
- Offer Letter, dated November 16, 2016, by and between the Registrant and Bart Henderson (Filed With SEC on September 5, 2017)
- License Agreement, dated March 21, 2013, by and between the Registrant (f/k/a Rhythm Metabolic, Inc.) and Ipsen Pharma S.A.S (Filed With SEC on September 5, 2017)
- Offer Letter, dated November 16, 2016, by and between the Registrant and Fred T. Fiedorek (Filed With SEC on September 5, 2017)
- Summary of Non-Employee Director Compensation Policy (Filed With SEC on September 5, 2017)
- Offer Letter, dated July 5, 2017, by and between the Registrant and Nithya Desikan (Filed With SEC on September 5, 2017)
- Offer Letter, dated July 17, 2017, by and between the Registrant and Hunter Smith (Filed With SEC on September 5, 2017)
- Development and Manufacturing Services Agreement, dated as of December 21, 2016, by and between Registrant and Recipharm Monts S.A.S (Filed With SEC on September 5, 2017)
- Consulting Agreement, dated June 12, 2017, by and between the Registrant and Bart Henderson (Filed With SEC on September 5, 2017)
- Lease, dated November 25, 2015, by and between 500 Boylston & 222 Berkeley Owner (DE) LLC and the Registrant (Filed With SEC on September 5, 2017)
- Amended and Restated Payroll Services Agreement, dated March 21, 2013, by and between the Registrant (f/k/a Rhythm Metabolic, Inc.) and Rhythm Pharmaceuticals, Inc (Filed With SEC on September 5, 2017)
- License Agreement dated January 4, 2016, by and between the Registrant and Camurus AB (Filed With SEC on September 5, 2017)
- Development and Manufacturing Services Agreement, dated July 17, 2013, by and between the Registrant (f/k/a Rhythm Metabolic, Inc.) and Peptisyntha Inc. (n/k/a Corden Pharma... (Filed With SEC on September 5, 2017)
